Increasing therapeutic efficacy in MPN.
In this issue of Blood, Bhagwat et al describe an elegant series of experiments showing that genetic deletion in the hematopoietic system of Janus kinase 2 (JAK2) abrogates initiation of myeloproliferative disease and substantial disease regression if deleted once disease is initiated.